189 related articles for article (PubMed ID: 11412645)
1. [Comparative study of piperacillin/tazobactam versus imipenem/cilastatin in febrile neutropenia (1994-1996)].
Figuera A ; Rivero N; Pajuelo F; Font P; Leyra F; de La Cámara R; Arranz R; María Fernández Rañada J
Med Clin (Barc); 2001 May; 116(16):610-1. PubMed ID: 11412645
[TBL] [Abstract][Full Text] [Related]
2. Imipenem-cilastatin versus piperacillin-tazobactam as monotherapy in febrile neutropenia.
Vural S; Erdem E; Gulec SG; Yildirmak Y; Kebudi R
Pediatr Int; 2010 Apr; 52(2):262-7. PubMed ID: 19744230
[TBL] [Abstract][Full Text] [Related]
3. Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study.
Sanz MA; Bermúdez A; Rovira M; Besalduch J; Pascual MJ; Nocea G; Sanz-Rodríguez C;
Curr Med Res Opin; 2005 May; 21(5):645-55. PubMed ID: 15969864
[TBL] [Abstract][Full Text] [Related]
4. Piperacillin-tazobactam vs. imipenem-cilastatin as empirical therapy in hematopoietic stem cell transplantation recipients with febrile neutropenia.
Jing Y; Li J; Yuan L; Zhao X; Wang Q; Yu L; Zhou D; Huang W
Clin Transplant; 2016 Mar; 30(3):263-9. PubMed ID: 26701371
[TBL] [Abstract][Full Text] [Related]
5. A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group.
Eklund AE; Nord CE
J Antimicrob Chemother; 1993 Jan; 31 Suppl A():79-85. PubMed ID: 8383657
[TBL] [Abstract][Full Text] [Related]
6. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis.
Jaccard C; Troillet N; Harbarth S; Zanetti G; Aymon D; Schneider R; Chiolero R; Ricou B; Romand J; Huber O; Ambrosetti P; Praz G; Lew D; Bille J; Glauser MP; Cometta A
Antimicrob Agents Chemother; 1998 Nov; 42(11):2966-72. PubMed ID: 9797234
[TBL] [Abstract][Full Text] [Related]
7. Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study.
Böhme A; Shah PM; Stille W; Hoelzer D
Eur J Med Res; 1998 Jul; 3(7):324-30. PubMed ID: 9682028
[TBL] [Abstract][Full Text] [Related]
8. Imipenem versus piperacillin/tazobactam for empiric treatment of neutropenic fever in adults.
Roohullah A; Moniwa A; Wood C; Humble M; Balm M; Carter J; Weinkove R
Intern Med J; 2013 Oct; 43(10):1151-4. PubMed ID: 23800137
[TBL] [Abstract][Full Text] [Related]
9. Meropenem versus piperacillin-tazobactam as empiric therapy for febrile neutropenia in pediatric oncology patients.
Sezgin G; Acipayam C; Ozkan A; Bayram I; Tanyeli A
Asian Pac J Cancer Prev; 2014; 15(11):4549-53. PubMed ID: 24969883
[TBL] [Abstract][Full Text] [Related]
10. Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital.
Saltoglu N; Dalkiran A; Tetiker T; Bayram H; Tasova Y; Dalay C; Sert M
Clin Microbiol Infect; 2010 Aug; 16(8):1252-7. PubMed ID: 19832720
[TBL] [Abstract][Full Text] [Related]
11. Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections.
Brismar B; Malmborg AS; Tunevall G; Wretlind B; Bergman L; Mentzing LO; Nyström PO; Kihlström E; Bäckstrand B; Skau T
Antimicrob Agents Chemother; 1992 Dec; 36(12):2766-73. PubMed ID: 1336347
[TBL] [Abstract][Full Text] [Related]
12. Randomized comparison of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of patients with intra-abdominal infection.
Erasmo AA; Crisostomo AC; Yan LN; Hong YS; Lee KU; Lo CM
Asian J Surg; 2004 Jul; 27(3):227-35. PubMed ID: 15564167
[TBL] [Abstract][Full Text] [Related]
13. Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections.
Naber KG; Savov O; Salmen HC
Int J Antimicrob Agents; 2002 Feb; 19(2):95-103. PubMed ID: 11850161
[TBL] [Abstract][Full Text] [Related]
14. Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections.
Niinikoski J; Havia T; Alhava E; Pääkkönen M; Miettinen P; Kivilaakso E; Haapiainen R; Matikainen M; Laitinen S
Surg Gynecol Obstet; 1993 Mar; 176(3):255-61. PubMed ID: 8382381
[TBL] [Abstract][Full Text] [Related]
15. Piperacillin/tazobactam versus imipenem: a double-blind, randomized formulary feasibility study at a major teaching hospital.
Marra F; Reynolds R; Stiver G; Bryce E; Sleigh K; Frighetto L; MacDougall C; Jewesson P
Diagn Microbiol Infect Dis; 1998 Jun; 31(2):355-68. PubMed ID: 9635910
[TBL] [Abstract][Full Text] [Related]
16. Piperacillin/tazobactam monotherapy versus piperacillin/tazobactam plus amikacin as initial empirical therapy for febrile neutropenia in children with acute leukemia.
Zengin E; Sarper N; Kılıç SC
Pediatr Hematol Oncol; 2011 May; 28(4):311-20. PubMed ID: 21524156
[TBL] [Abstract][Full Text] [Related]
17. Cost efficacy of tazobactam/piperacillin versus imipenem/cilastatin in the treatment of intra-abdominal infection.
Dietrich ES; Schubert B; Ebner W; Daschner F
Pharmacoeconomics; 2001 Jan; 19(1):79-94. PubMed ID: 11252548
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial comparing netilmicin plus imipenem-cilastatin versus netilmicin plus ceftazidime as empiric therapy for febrile neutropenic bone marrow transplant recipients.
Laszlo D; Bacci S; Bosi A; Fanci R; Guidi S; Saccardi R; Vannucchi AM; Rossi Ferrini P
J Chemother; 1997 Apr; 9(2):95-101. PubMed ID: 9176746
[TBL] [Abstract][Full Text] [Related]
19. Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer).
Biron P; Fuhrmann C; Cure H; Viens P; Lefebvre D; Thyss A; Viot M; Soler-Michel P; Rollin C; Grès JJ
J Antimicrob Chemother; 1998 Oct; 42(4):511-8. PubMed ID: 9818751
[TBL] [Abstract][Full Text] [Related]
20. Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice.
Shono Y; Docampo MD; Peled JU; Perobelli SM; Velardi E; Tsai JJ; Slingerland AE; Smith OM; Young LF; Gupta J; Lieberman SR; Jay HV; Ahr KF; Porosnicu Rodriguez KA; Xu K; Calarfiore M; Poeck H; Caballero S; Devlin SM; Rapaport F; Dudakov JA; Hanash AM; Gyurkocza B; Murphy GF; Gomes C; Liu C; Moss EL; Falconer SB; Bhatt AS; Taur Y; Pamer EG; van den Brink MRM; Jenq RR
Sci Transl Med; 2016 May; 8(339):339ra71. PubMed ID: 27194729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
